SPY001 is a novel, half-life extended monoclonal antibody targeting α4β7 for the potential treatment of IBD
SPY002 is a novel, half-life extended monoclonal antibody targeting TL1A for the potential treatment of IBD
SPY003 is a novel, half-life extended monoclonal antibody targeting IL-23 for the potential treatment of IBD
SPY120 is a combination of SPY001 (anti-α4β7) and SPY002 (anti-TL1A) for the potential treatment of IBD
SPY130 is a combination of SPY001 (anti-α4β7) and SPY003 (anti-IL-23) for the potential treatment of IBD
SPY230 is a combination of SPY002 (anti-TL1A) and SPY003 (anti-IL-23) for the potential treatment of IBD
SPY072 is a novel, half-life extended monoclonal antibody targeting TL1A for the potential treatment of rheumatological diseases including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA)
Product candidates discussed are investigational and currently being studied in clinical trials. Their safety and efficacy have not been established and they have not been approved for any use by FDA, the European Commission, or any other health authority.